Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Immunome Inc Market Cap
Based on ratings from 7 stock analysts, the Immunome Inc stock price is expected to increase by 115.83% in 12 months. This is calculated by using the average 12-month stock price forecast for Immunome Inc. The lowest target is $21 and the highest is $38. Please note analyst price targets are not guaranteed and could be missed completely.
Immunome Inc has a total of 7 Wall St Analyst ratings. There are 7 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Immunome Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of IMNM.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Biren Amin Piper Sandler | Overweight | $21 | Maintains | Nov 14, 2024 |
| Sudan Loganathan Stephens & Co. | Overweight | $30 | Initiates | Nov 8, 2024 |
| David Nierengarten Wedbush | Outperform | $33 | Reiterates | Oct 25, 2024 |
| David Nierengarten Wedbush | Outperform | $33 | Reiterates | Aug 13, 2024 |
| Biren Amin Piper Sandler | Overweight | $23 | Maintains | Aug 13, 2024 |
| Biren Amin Piper Sandler | Overweight | $27 | Initiates | May 31, 2024 |
| Brian Cheng JP Morgan | Overweight | $24 | Initiates | Apr 30, 2024 |
| Michael Schmidt Guggenheim | Buy | $35 | Initiates | Apr 15, 2024 |
| David Nierengarten Wedbush | Outperform | $33 | Maintains | Apr 1, 2024 |
| David Nierengarten Wedbush | Outperform | $19 | Maintains | Jan 23, 2024 |
| David Nierengarten Wedbush | Outperform | $12 | Initiates | Dec 19, 2023 |
| Pete Stavropoulos Cantor Fitzgerald | Overweight | $8 | Reiterates | Mar 20, 2023 |
| Matthew Barcus Chardan Capital | Buy | $8 | Maintains | Mar 17, 2023 |
| Brian Cheng Cantor Fitzgerald | Overweight | $35 | Initiates | Oct 29, 2021 |
Chardan Capital | Buy | Initiates | Oct 27, 2020 |
When did it IPO
2020
Staff Count
55
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Clay B. Siegall Ph.D.
Market Cap
$857.0M
In 2023, IMNM generated $14.0M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that IMNM's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 02 Dec 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Immunome, Inc. granted stock options to purchase 210,500 shares to 15 new employees as part of its 2024 Inducement Plan, aimed at enhancing its targeted cancer therapies.
Why It Matters - The grant of stock options to new employees indicates Immunome's growth and commitment to attracting talent, potentially boosting innovation and future performance, which can impact stock value.
Wed, 27 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Immunome, Inc. (Nasdaq: IMNM) will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 4:30 p.m. ET, accessible via their website.
Why It Matters - Management participation in a major healthcare conference signals potential insights into company strategy and pipeline developments, influencing investor sentiment and stock valuation.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Immunome announced its third quarter 2024 financial results and provided a business update, detailing recent developments and financial performance.
Why It Matters - Immunome's Q3 2024 financial results and business update can signal its growth potential and operational performance, influencing investor sentiment and stock valuation.
Wed, 13 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Immunome, Inc. (IMNM) reported a quarterly loss of $0.78 per share, exceeding the Zacks estimate of $0.60 and worsening from a loss of $0.36 per share a year earlier.
Why It Matters - Immunome's larger-than-expected quarterly loss may indicate ongoing financial struggles, potentially affecting stock performance and investor sentiment.
Tue, 05 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Immunome, Inc. will have CEO Clay Siegall speaking at Guggenheim's Healthcare Innovation Conference on November 13 at 10:30 AM ET. A live audio webcast will be available.
Why It Matters - Clay Siegall's participation in a major healthcare conference highlights Immunome's visibility and potential for partnerships, influencing investor sentiment and stock performance.
Tue, 29 Oct 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Immunome, Inc. (Nasdaq: IMNM) presented promising preclinical data for its ROR1-targeted ADC, IM-1021, at the EORTC-NCI-AACR Symposium, showcasing its novel topoisomerase I linker payload.
Why It Matters - Promising preclinical data for Immunome's IM-1021 may indicate potential for innovative cancer treatments, influencing market perception and investment in biotech stocks.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
